Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
AstraZeneca
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Bristol-Myers Squibb
AstraZeneca
Bristol-Myers Squibb
Hoffmann-La Roche
Bristol-Myers Squibb
Bristol-Myers Squibb
Daiichi Sankyo
Merck Sharp & Dohme LLC
AbbVie
Eisai Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Hoffmann-La Roche
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Ono Pharmaceutical Co. Ltd
National Cancer Institute (NCI)